Cart
sales@molnova.com
WAY-260022
CAS No. 850692-43-2
WAY-260022( —— )
Catalog No. M33964 CAS No. 850692-43-2
WAY-260022 is an orally available and selective norepinephrine transporter protein inhibitor that displays inhibitory effects on serotonin and dopamine transporter proteins.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 411 | In Stock |
|
| 10MG | 562 | In Stock |
|
| 25MG | 866 | In Stock |
|
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameWAY-260022
-
NoteResearch use only, not for human use.
-
Brief DescriptionWAY-260022 is an orally available and selective norepinephrine transporter protein inhibitor that displays inhibitory effects on serotonin and dopamine transporter proteins.
-
DescriptionWAY-260022 is an orally available and selective norepinephrine transporter protein inhibitor that displays inhibitory effects on serotonin and dopamine transporter proteins.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayGPCR/G Protein
-
TargetDopamine Receptor
-
RecptorDopamine Receptor | Serotonin Transporter | Norepinephrine
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number850692-43-2
-
Formula Weight400.48
-
Molecular FormulaC21H31F3N2O2
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES[C@H](CN1C[C@H](C)N[C@H](C)C1)(C2(O)CCCCC2)C3=CC(OC(F)(F)F)=CC=C3
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
molnova catalog
related products
-
CP-226269
CP-226269 is a potent dopamine D4 receptor agonist that regulates calcium flux and has an EC50 value of 32.0 nM. CP 226269 can be used to study neurological disorders such as schizophrenia.
-
Lensiprazine
Lensiprazine (SLV314) is a potent dopamine D(2) receptor antagonist that acts as a serotonin reuptake inhibitor , and can be used to study bipolar disorder and schizophrenia.
-
LE 300
LE 300 represents a structurally novel type of antagonists acting preferentially at the dopamine D(1)/D(5)receptors and the serotonin 5-HT(2A)receptor.
